AXTI · AXT Inc

Current Thesis

AXT's contracted indium phosphide demand supports a recovery thesis that requires delivery of July's revenue guidance and preservation of the reclaimed placement shelf. The measurable change since the September 3 assessment is the September 11, 2026 adjusted close of $64.77: the market has recovered both the previously lost $58 level and the April 21 placement price of $64.25. That repairs the earlier assessment of a failed price structure; it does not establish that customer deposits have become shipments.

The narrative is maturing — this is an inference from the customer agreements dated June 25 and July 26, 2026, followed by the July 30 results and the September 11 recovery above the placement shelf. The contracted-demand story is already public, while the shares remain 54.0% below their adjusted 52-week high as of September 11. The case resolves positively if third-quarter revenue meets management's approximately $66.0 million guidance and the reporting-week close remains above $64.25 before a weekly close below $52 invalidates it.

Bullish and bearish views on AXT Inc

The model's bull view on AXT Inc (AXTI), in brief: Revenue already reflects stronger demand. The bear view: Contract terms do not establish receipt. Both cases follow in full.

Bull Case

• Revenue already reflects stronger demand. AXT's July 30, 2026 second-quarter report recorded $47.59 million in revenue, including record indium phosphide revenue of $30.7 million. Reported gross margin was 44.9%, compared with 29.6% in the first quarter; these are measured results rather than forecasts of optical demand.
• Contracts extend beyond the quarter. The Lumentum agreement entered July 26, 2026 runs through 2031 and specifies two deposits of $43.5 million each, applied as shipment credits. Coherent's agreement effective June 25, 2026 specifies a $22.29 million prepayment; the commercial case fails if committed demand is cancelled or does not support the guided revenue conversion.
• Guidance limits the permit assumption. On the July 30, 2026 earnings call, management guided to approximately $66.0 million of third-quarter revenue using already-granted export permits or products outside the restricted set. Revenue below that guidance would contradict the near-term conversion case even without a new permit restriction.

Bear Case

• Contract terms do not establish receipt. The July 26, 2026 Lumentum agreement requires the initial deposit within thirty business days of entry. That contractual obligation is not evidence that payment occurred; an explicit disclosure of nonpayment, deferral or renegotiation would break the funded-capacity interpretation.
• Export approvals remain a constraint. Management's July 30, 2026 call modelled China at 40–60% of revenue and said future export-permit timing could not be forecast. A disclosed permit denial affecting committed shipments, or guidance reduced because of approvals, would confirm this risk.
• Subsidiary financing remains unresolved. Tongmei's June 26, 2026 withdrawal of its STAR Market application triggered a redemption right associated with approximately $49 million of earlier private-equity investment, according to the prior disclosed financing terms. Exercise of that right would turn a contingent financing issue into a cash obligation.

Setup & Price Structure

The September 11, 2026 adjusted close of $64.77 sits above the April 21 placement shelf at $64.25, whereas the September 2 close of $56.95 was below it. The latest supplied series reports a three-month price decline of 33.4% and a 14-day relative strength index of 43.5 as of September 11. These observations establish a recovery across the shelf, but the available observations are too few to establish a durable base or expanding participation.

The $64.25 placement price is the immediate structural test; a weekly close back below $64.25 would negate the reclamation, while $52 remains the thesis-ending research threshold retained from the September 3 publication. That lower threshold is an analytical boundary, not a demonstrated support level. No moving-average value or current short-interest measurement is available here, so neither trend extension nor a short-covering explanation is established.

Positioning evidence remains historical: director Leonard J. LeBlanc's Form 4 filed August 19, 2026 disclosed a sale of 4,000 shares on August 17, with the trading-plan checkbox unmarked. Separately, Benzinga's analyst-action table checked September 13 still lists July 31 as its latest action date, including Needham's $90 target and B. Riley's $55 target. Those dated opinions do not establish fresh institutional demand behind the recovery. Benzinga analyst-action history.

Catalyst Calendar (next 30 days)

• 2026-09-21 to 2026-09-22 — Morgan Stanley Asia Best Corporate Day, New York. AXT announced participation on August 17, 2026. Any disclosed update on Lumentum payment receipt or export approvals would test the conversion thesis; attendance alone would resolve neither issue. AXT conference announcement.
• ~2026-10-29, estimated — Third-quarter results, beyond this calendar window. The date appeared in the September 3 coverage's earnings listings; company confirmation is not established here. This is the decisive financial test of the approximately $66.0 million revenue guidance issued July 30, 2026.

The September 10 B. Riley conference date announced by AXT on August 17 has elapsed. Its passage is not evidence of deposit receipt, cancellation or a change in guidance. AXT conference announcement.

What Would Change Our Mind

Failure of the recovered structure would end the market thesis at a weekly close below $52, the published September 3 research boundary beneath the $58–$64.25 recovery zone. Earlier deterioration would be observable through a weekly close below $64.25, the April 21 placement shelf reclaimed by September 11.

The operating thesis fails independently if reported third-quarter revenue falls below the approximately $66.0 million guidance issued July 30, 2026, or AXT discloses cancellation or nonpayment under the July 26 Lumentum agreement. Conversely, delivery of that revenue guidance together with a reporting-week close above $64.25 would satisfy the stated recovery case, provided the $52 weekly invalidation had not already occurred.

Correlation Notes

This remains a single-name contract-conversion thesis rather than a demonstrated group trend. Benzinga's August 24, 2026 premarket report listed AXTI alongside declining Coherent and Lumentum shares when Applied Optoelectronics announced a $600 million offering. That shared session identifies possible exposure to optical-sector financing news; the sample is too small to support a correlation claim.

Coherent's August 12, 2026 earnings call reported 80% year-over-year growth in indium phosphide laser production during the June quarter and said required substrates had been secured for its production ramp. This is customer-side evidence of activity, but it does not identify AXT's shipment share. AXT's own third-quarter revenue remains the observable test of whether that demand reaches its accounts.